Advisory Research Inc Nuvalent, Inc. Transaction History

Advisory Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$42.42 - $80.28 $635,706 - $1.2 Million	14,986 Added 226.37%	21,606 $1.59 Million
Q3 2023 Nov 13, 2023	SELL	$39.12 - $49.85 $183,864 - $234,295	-4,700 Reduced 41.52%	6,620 $304,000
Q2 2023 Aug 14, 2023	SELL	$23.58 - $44.68 $59,138 - $112,057	-2,508 Reduced 18.14%	11,320 $477,000
Q1 2023 May 12, 2023	SELL	$25.42 - $33.52 $222,857 - $293,869	-8,767 Reduced 38.8%	13,828 $360,000
Q4 2022 Feb 13, 2023	BUY	$18.46 - $36.37 $89,770 - $176,867	4,863 Added 27.42%	22,595 $672,000
Q3 2022 Nov 14, 2022	BUY	$13.55 - $19.92 $240,268 - $353,221	17,732 New	17,732 $345,000

210

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.08B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.